Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680573 · ClinicalTrials.gov registry record · Phase 1
The Effect of Antioxidants on Skin Blood Flow-BH4
A Phase 1 study, sponsored by The University of Texas at Arlington.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03680573: Completed Phase 1 study, sponsored by The University of Texas at Arlington.
NCT03680573 is a Phase 1 study that has completed, run by The University of Texas at Arlington. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03680573, a Phase 1 study, has completed, sponsored by The University of Texas at Arlington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The goal of this study is to examine possible mechanisms of heightened vasoconstriction in Black/African American men and women as possible links to the elevated prevalence of cardiovascular dysfunction and disease. The main targets in this study are sources of oxidative stress
Primary Outcome
To establish impaired blood flow response to local administration of Mch in African American relative to Caucasians. Mch will be administered using intradermal microdialysis in separate doses while the skin blood flux response will be determined using laser Doppler fluxmetry. All changes in flux will be normalized and reported as a percentage of maximal flux. The role of oxidative stress and low nitric oxide synthase cofactors will be assessed using infusions of apocynin/allopurinol and tetrahyd
Interventions
- DRUG Allopurinol
- DRUG BH4
- DRUG NG Nitro L Arginine Methyl Ester
- DRUG Apocynin
- DRUG Control: Lacated Ringers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-01-08 |
| Est. Completion | 2018-05-05 |
| Phase | Phase 1 |
What the finished NCT03680573 record still lists
NCT03680573 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 5 interventions - of which Allopurinol is the first listed.
NCT03680573 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03680573 about?
NCT03680573 is a clinical study titled "The Effect of Antioxidants on Skin Blood Flow-BH4". The goal of this study is to examine possible mechanisms of heightened vasoconstriction in Black/African American men and women as possible links to the elevated prevalence of cardiovascular dysfunction and disease. The main targets in this study are sources of oxidative stress
What is the current status of trial NCT03680573?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-01-08. Estimated completion is 2018-05-05.
What interventions are being tested in trial NCT03680573?
The interventions under investigation include: Allopurinol (DRUG), BH4 (DRUG), NG Nitro L Arginine Methyl Ester (DRUG), Apocynin (DRUG), Control: Lacated Ringers (DRUG).
Who is sponsoring clinical trial NCT03680573?
This trial is sponsored by The University of Texas at Arlington, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03680573's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI